{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:03:20Z","timestamp":1780319000663,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11864-020-00763-7","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T16:03:30Z","timestamp":1593446610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Satya","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"17","key":"763_CR1","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675\u201384.","journal-title":"J Clin Oncol"},{"key":"763_CR2","doi-asserted-by":"publisher","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","DOI":"10.1093\/annonc\/mdz011"},{"issue":"2","key":"763_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascieto","year":"2018","unstructured":"Ascieto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2018;5(2):187\u201394.","journal-title":"JAMA Oncol"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"R Motzer","year":"2015","unstructured":"Motzer R, Escudier B, McDermott D, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"B Rini","year":"2019","unstructured":"Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"P Nghiem","year":"2016","unstructured":"Nghiem P, Bhatia S, Lipson E, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542\u201352.","journal-title":"N Engl J Med"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"issue":"6349","key":"763_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"57","author":"D Le","year":"2017","unstructured":"\u2022\u2022 Le D, Durham J, Smith K, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;57(6349):409\u201313 A seminal article which suggested the predictive power of microsatellite instability-high tumor status, across tumor histology, to predict benefit from the checkpoint inhibitor pembrolizumab.","journal-title":"Science"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828\u201333.","journal-title":"J Immunother"},{"key":"763_CR10","unstructured":"SEER Database 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"issue":"4","key":"763_CR11","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1200\/JCO.2019.37.4_suppl.191","volume":"37","author":"M Pishvaian","year":"2019","unstructured":"\u2022\u2022 Pishvaian M, Blais E, Brody J, et al. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: results from the Know Your Tumor (KYT) program. J Clin Oncol. 2019;37(4):S191 An important publication suggesting that DDR mutations are more prevalent in PDA than previously thought and furthermore, that DDR mutations in tumors predict sensitivity to platinum chemotherapy.","journal-title":"J Clin Oncol"},{"key":"763_CR12","doi-asserted-by":"publisher","unstructured":"Heeke A, Pishvaian M, Lynce F, et al. Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.17.00286.","DOI":"10.1200\/PO.17.00286"},{"issue":"4","key":"763_CR13","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1200\/JCO.2019.37.4_suppl.285","volume":"37","author":"S Dreyer","year":"2019","unstructured":"Dreyer S, Paulus-Hock V, Upstill-Goddard R, et al. Defining DNA damage repair deficiency and replication stress in pancreatic cancer. J Clin Oncol. 2019;37(4):S285.","journal-title":"J Clin Oncol"},{"key":"763_CR14","doi-asserted-by":"publisher","unstructured":"Schroff R, Hendifar A, McWilliams R, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. J Prescis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.17.00316.","DOI":"10.1200\/PO.17.00316"},{"issue":"4","key":"763_CR15","doi-asserted-by":"publisher","first-page":"S297","DOI":"10.1200\/JCO.2018.36.4_suppl.297","volume":"36","author":"T Golan","year":"2018","unstructured":"\u2022\u2022 Golan T, Varadhachary G, Sela T, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018;36(4):S297 An important study which sought to expand the role of PARP inhibitors to PDA patients beyond those with germline BRCA mutations. Preliminary results from this study suggest that PARP inhibitors have a role in PDA tumors with somatic mutations in other DDR genes.","journal-title":"J Clin Oncol"},{"key":"763_CR16","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Reiss Binder K, Mick R, O\u2019Hara M, et al. CT234 - a phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Cancer Discov. 2019. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2019-043 An important study which suggested the biggest benefit of PARP inhibitors in mPDA patients may be in the platinum chemotherapy sensitive setting. The study also included patients beyond those with just germline BRCA mutations.","DOI":"10.1158\/2159-8290.CD-NB2019-043"},{"issue":"1\u20132","key":"763_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.18632\/oncoscience.392","volume":"5","author":"L Perkhofer","year":"2018","unstructured":"Perkhofer L, Illing A, Gout J, et al. Precision medicine meets the DNA damage response in pancreatic cancer. Oncoscience. 2018;5(1\u20132):6\u20138.","journal-title":"Oncoscience"},{"issue":"8","key":"763_CR18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17(8):1670\u201382.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"763_CR19","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1080\/15384101.2015.1104437","volume":"14","author":"A Estrada-Bernal","year":"2015","unstructured":"Estrada-Bernal A, Chatterjee M, Hague SJ, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015;14(23):3713\u201324.","journal-title":"Cell Cycle"},{"issue":"3","key":"763_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler R, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33(3):244\u201350.","journal-title":"J Clin Oncol"},{"key":"763_CR21","doi-asserted-by":"publisher","unstructured":"Hopkins T, Ainsworth W, Ellis P, et al. PARP1 Trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0138.","DOI":"10.1158\/1541-7786.MCR-18-0138"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","volume":"89","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018;89:19\u201326.","journal-title":"Eur J Cancer"},{"key":"763_CR23","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1903387 A practice-changing study which demonstrated the benefit of PARP inhibitors in the platinum sensitive maintenance setting for germline BRCA mutant mPDA patients in a randomized clinical trial. This study garnered olaparib an FDA indication for maintenance therapy.","DOI":"10.1056\/NEJMoa1903387"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"\u2022 Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Eng J Med. 2018;379:2495\u2013505 An important paper describing the activity of PARP inhibitors in ovarian cancer. The activity of olaparib in this study should be contrasted with the activity of the agent in pancreatic adenocarcinoma.","journal-title":"N Eng J Med"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"J Litton","year":"2018","unstructured":"Litton J, Rugo H, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"issue":"27","key":"763_CR26","doi-asserted-by":"publisher","first-page":"44073","DOI":"10.18632\/oncotarget.17237","volume":"8","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Myzak MC, Johnson BA, et al. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget. 2017;8(27):44073\u201381.","journal-title":"Oncotarget"},{"issue":"7","key":"763_CR27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cncr.31218","volume":"124","author":"EM O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124(7):1374\u201382.","journal-title":"Cancer"},{"key":"763_CR28","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 O\u2019Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase ii trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.19.02931 An important study demonstrating the viability of gemcitabine plus cisplatin in PDA patients with germline deficits in BRCA and PALB2. This study also suggested that though veliparib increased RR when combined with gemcitabine plus cisplatin in patients, it did not improve survival outcomes.","DOI":"10.1200\/JCO.19.02931"},{"issue":"15","key":"763_CR29","doi-asserted-by":"publisher","first-page":"S4015","DOI":"10.1200\/JCO.2019.37.15_suppl.4015","volume":"37","author":"M Pishvaian","year":"2019","unstructured":"Pishvaian M, Wang H, Parenti S, et al. A phase I\/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients with metastatic pancreatic cancer (mPDAC). J Clin Oncol. 2019;37(15):S4015.","journal-title":"J Clin Oncol"},{"key":"763_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 5(9):a012716 A review which highlights the critical stimuli which trigger ATR and ATM along with the mechanisms and targets of the DDR-coordinating kinases.","DOI":"10.1101\/cshperspect.a012716"},{"key":"763_CR31","doi-asserted-by":"crossref","unstructured":"Dreyer S, Paulus-Hock V, Lampraki EM, et al. Defining DDR defectiveness in pancreatic cancer. J Clin Oncol. 2017;35(suppl;abstr 4115).","DOI":"10.1200\/JCO.2017.35.15_suppl.4115"},{"issue":"1","key":"763_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","volume":"107","author":"J Morton","year":"2010","unstructured":"Morton J, Timpson P, Karim S, et al. Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"33323","DOI":"10.1038\/srep33323","volume":"6","author":"S Lal","year":"2016","unstructured":"Lal S, Zarei M, Chand S, et al. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Sci Rep. 2016;6:33323.","journal-title":"Sci Rep"},{"issue":"9","key":"763_CR34","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S1470-2045(19)30537-6","volume":"20","author":"T Burki","year":"2019","unstructured":"Burki T. AZD1775 plus chemoradiotherapy for pancreatic cancer. Lancet Oncol. 2019;20(9):e472.","journal-title":"Lancet Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00763-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T23:20:44Z","timestamp":1624922444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00763-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00763-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"29 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Satya Das and Dana Cardin declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"62"}}